Knoll Capital Management LLC Purchases 400,000 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Knoll Capital Management LLC boosted its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 199.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 600,400 shares of the biopharmaceutical company’s stock after purchasing an additional 400,000 shares during the period. Ocular Therapeutix comprises about 2.6% of Knoll Capital Management LLC’s portfolio, making the stock its 10th largest holding. Knoll Capital Management LLC owned 0.39% of Ocular Therapeutix worth $5,223,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in OCUL. Atlas Capital Advisors LLC acquired a new stake in shares of Ocular Therapeutix during the 2nd quarter worth about $34,000. Amalgamated Bank grew its holdings in shares of Ocular Therapeutix by 37.9% during the 2nd quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 1,481 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Ocular Therapeutix by 22.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 1,015 shares during the last quarter. Algert Global LLC bought a new stake in Ocular Therapeutix during the 2nd quarter worth approximately $69,000. Finally, Capital Performance Advisors LLP acquired a new position in shares of Ocular Therapeutix in the 3rd quarter worth approximately $70,000. Institutional investors own 59.21% of the company’s stock.

Ocular Therapeutix Stock Up 3.2 %

Shares of NASDAQ OCUL opened at $10.06 on Friday. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. Ocular Therapeutix, Inc. has a one year low of $2.16 and a one year high of $11.77. The firm’s 50 day simple moving average is $9.96 and its two-hundred day simple moving average is $8.22.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Robert W. Baird dropped their target price on shares of Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. HC Wainwright upped their price objective on shares of Ocular Therapeutix from $14.00 to $15.00 and gave the company a “buy” rating in a report on Friday, November 15th. Finally, Scotiabank assumed coverage on shares of Ocular Therapeutix in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $22.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $16.71.

Insider Transactions at Ocular Therapeutix

In related news, insider Jeffrey S. Heier sold 2,948 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $9.01, for a total value of $26,561.48. Following the completion of the sale, the insider now owns 269,059 shares of the company’s stock, valued at $2,424,221.59. This trade represents a 1.08 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 3.50% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.